about
CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individualsFour years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyProspective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trialA case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon αNeurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected patients with advanced disease.Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.Unmasking tuberculosis in the era of antiretroviral treatment.Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals.Occupational HIV Infection in a Research Laboratory With Unknown Mode of Transmission: A Case Report.A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.After first-line ART: towards an evidence-based SECOND-LINE.Imported ciprofloxacin-resistant Neisseria meningitidis.Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial.Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome.Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk?Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimenReal-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis CSimilar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV TherapyUnmasked tuberculosis or lymphoma in late AIDS presenters: a difficult differential diagnosisHIV testing: a must for patients with inflammatory bowel disease?ReplyReplyComparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort
P50
Q28751971-3E2C8246-905F-4053-B5A5-6F6F914CC221Q30710478-76033562-BCB5-43AB-8C45-319A55A13D8FQ31168033-E59AEA5C-C915-430B-9E23-CADC24010CBCQ35074381-6415B6D0-29DF-4E95-8963-1208816DF3CFQ35290680-B815D1EB-9FCC-4922-9DB6-D34EA43015B3Q35872249-9652D972-8034-4F42-94A9-49FD85889502Q36916575-6A27818D-3A1A-4BC5-8243-46E9F8F6CC2CQ37308894-C0DC968A-55C5-44A1-A83C-96782D3722FCQ37946719-52C8FDCD-3E61-409B-99CB-725C356582B6Q39399725-EF8088AE-44F6-425B-9927-532BCD37696DQ40261346-A39C9580-9F36-460D-863A-56D87F3535BCQ40390935-96795F74-4D6F-4B4B-AD4E-736101B5E281Q41927450-09850D8A-57E9-42C8-8C9D-CB119EA8481DQ42167549-EF8CCD08-1AAF-4171-AB17-97D05DF17559Q42258902-595A1571-8C88-473B-9743-B43194B90C8CQ42832082-978E4AAA-5025-43EC-94DE-248BC9855687Q43162451-9FDE2FE4-CF48-412F-8E77-77A33ACE70BAQ43200013-18BE92A8-3C9B-4186-B5AA-BF276C215302Q43450712-6A042247-49D3-4C4C-8842-EA3E35D751EBQ43830205-F30BD0F3-D348-4EEE-BCC2-B1156C20699EQ46057921-F2BD12A2-118B-4E98-B15E-677AD97B8AC8Q47296847-3DB27D66-CAB5-4C8A-B7DB-036B172A850BQ48585925-B714DD0F-909D-454E-865E-9F1D57EA7EA4Q58167843-5CD24BC8-D93D-46B0-8621-127DFFD1115DQ59350177-558D9EBA-B954-460B-93BD-474AC06FD44AQ60621766-78DABAAF-BA26-43BA-8B95-7339D0C2D503Q60621772-023E4790-5DE5-4B7C-8F64-537FB496D505Q84902528-F5EEAA08-2741-457A-A4FA-D05C52B34395Q95404503-5798B9DB-A880-43A0-B08F-245B1D8151B1Q95430776-B2C6EBAA-8A76-4A06-BDC8-29EE6CC99ACEQ95592483-9DC1E9AB-C6B2-46A7-AA31-21012389AD8C
P50
description
researcher ORCID ID = 0000-0002-4447-2574
@en
name
Alessandro Soria
@ast
Alessandro Soria
@en
Alessandro Soria
@es
Alessandro Soria
@nl
type
label
Alessandro Soria
@ast
Alessandro Soria
@en
Alessandro Soria
@es
Alessandro Soria
@nl
prefLabel
Alessandro Soria
@ast
Alessandro Soria
@en
Alessandro Soria
@es
Alessandro Soria
@nl
P1153
20434485600
P21
P31
P496
0000-0002-4447-2574